Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Preclinical models support the synergistic potential of seralutinib and sotatercept in treating pulmonary arterial hypertension

Friday, January 31, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Recent preclinical studies indicate that the combination of seralutinib and sotatercept may have synergistic effects in treating pulmonary arterial hypertension (PAH). These findings suggest that the dual therapy could enhance treatment efficacy and improve patient outcomes. Further research is needed to validate these results in clinical settings.
Price reaction · baseline $0.9637 (2025-01-30 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Preclinical models show promising results for seralutinib and sotatercept.
  • Synergistic effects may enhance treatment for pulmonary arterial hypertension.
  • Potential to improve patient outcomes in PAH.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Preclinical models support the synergistic potential of seralutinib and sotatercept in treating pulmonary arterial hypertension
PVRI – January 2025a
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the focus of the preclinical models?

The preclinical models focus on the synergistic potential of seralutinib and sotatercept in treating pulmonary arterial hypertension.

What condition are seralutinib and sotatercept targeting?

They are targeting pulmonary arterial hypertension (PAH).

What is the significance of the findings?

The findings suggest that the combination may enhance treatment efficacy for PAH.

Are there any negative aspects mentioned?

No specific negative aspects were mentioned in the article.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib sotatercept pulmonary arterial hypertension PAH preclinical models
Last updated: Jan 31, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →